TMB Poster Request Form

Poster: Tumor Mutational Burden and Genomic Profiling from FFPE Research Samples using a Targeted Next-Generation Sequencing Assay on Ion Torrent

High Tumor Mutational Burden (TMB) has shown association with benefit from immune checkpoint blockade therapies. While TMB as computed from whole exome sequencing (WES) is still a gold standard, the high input material (tumor and germline DNA) requirement and complex bioinformatics refrains exploring this biomarker in individual labs. This study describes the development of a PCR-based targeted panel for computing TMB and detecting important variants from FFPE research samples.